Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Oramed Pharmaceuticals Inc
ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
Analytics
WallStreetin tavoitehinta
3.25 USDP/E-suhde
4.549Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut ORMP
Osinkoanalytiikka ORMP
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria ORMP
Osakkeen arvostus ORMP
Talousasiat ORMP
Tuloksia | 2019 | Dynamiikka |